Leerink maintains Rocket Pharmaceuticals Market Perform, $4 target

Leerink Partners maintained a Market Perform rating on Rocket Pharmaceuticals and set a $4.00 price target, implying 61.3% upside versus the Oct 6 close of $2.48.